TIDMAVCT

RNS Number : 8226C

Avacta Group PLC

13 February 2020

13 February 2020

Avacta Group plc

("Avacta", the "Group" or the "Company")

Notice of Results

Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, will announce its financial results for the 17 months ended 31 December 2019 on Tuesday, 21 April 2020.

An analyst briefing given by Alastair Smith, Chief Executive Officer and Tony Gardiner, Chief Financial Officer, will be held at 09.30 hrs on Tuesday, 21 April 2020 at finnCap's offices, 60 New Broad St, London EC2M 1JJ.

- Ends -

For further information from Avacta Group plc, please contact:

 
 Avacta Group plc                        Tel: +44 (0)844 414 0452 
  Alastair Smith, Chief Executive         www.avacta.com 
  Officer 
  Tony Gardiner, Chief Financial 
  Officer 
 finnCap Ltd (Nominated Adviser          Tel: +44 (0)207 220 0500 
  and Joint Broker)                       www.finncap.com 
  Geoff Nash / Giles Rolls - Corporate 
  Finance 
  Tim Redfern - ECM 
 
   Yellow Jersey PR (Financial Media       Tel: +44 (0)7764 947 137 
   and IR)                                 Tel: +44 (0)7951 402 336 
   Sarah Hollins                           avacta@yellowjerseypr.com 
   Henry Wilkinson 
                                           Tel: +44 (0)7787 502 947 
   Zyme Communications (Trade and          katie.odgaard@zymecommunications.com 
   Regional Media) 
   Katie Odgaard

About Avacta Group plc - https://www.avacta.com

Avacta is developing novel cancer immunotherapies combining its two proprietary platforms - Affimer(R) biotherapeutics and pre|CISION(TM) tumour targeted chemotherapy. With this approach, the Company aims to address the lack of a durable response to current immunotherapies experienced by most patients. The Company's therapeutics development activities are based in Cambridge, UK.

The Company benefits from near-term revenues generated from Affimer reagents for diagnostics, bioprocessing and research, through a separate business unit based in Wetherby, UK.

The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken, and the reliance on an animal's immune response, to generate new antibodies; poor specificity in many cases; large size and cost.

Avacta's pre|CISION platform, activates chemotherapy only in the tumour, thereby limiting systemic exposure and damage to healthy tissues, and thus improving the overall safety and therapeutic potential of these powerful anti-cancer treatments.

By combining these two platforms the Company is building a wholly owned pipeline of novel cancer therapies with the aim of creating effective treatments for all cancer patients including those who do not respond to existing immunotherapies. Avacta expects to take its first drug, a pre|CISION targeted form of the standard-of-care Doxorubicin, into the clinic in the middle of 2020.

Avacta has established drug development partnerships with pharma and biotech, including with Moderna Therapeutics Inc., a collaboration with LG Chem to develop treatments for autoimmune and inflammatory diseases worth up to $310m, a partnership with ADC Therapeutics to develop Affimer drug conjugates and a joint venture in South Korea with Daewoong Pharmaceuticals to develop the next generation of stem cell therapies that incorporate Affimer immuno-modulators. Avacta actively seeks to license its proprietary platforms in a range of therapeutic areas.

The Avacta diagnostics business unit works with partners world-wide to develop Affimers for evaluation by those third parties with the objective of establishing royalty bearing license deals. The Company is also developing a small in-house pipeline of Affimer-based diagnostic assays for licensing.

To register for news alerts by email go to www.avacta.com/investor-news-email-alerts

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NORSFUFMEESSELE

(END) Dow Jones Newswires

February 13, 2020 02:01 ET (07:01 GMT)

Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Avacta
Grafico Azioni Avacta (LSE:AVCT)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Avacta